Allergan / Latisse
BIMATOPROST OPHTHALMIC SOLUTION 0.03%
It works, unambiguously — 78% of users versus 18% on vehicle at sixteen weeks. It can also permanently darken your iris and hollow the fat pad behind your upper eyelid. Both facts are on the same label, which is exactly why this review exists.
Worth buying for a specific person with a specific problem. Read who.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
We earn nothing on this link. Read the iris pigmentation and periorbital fat atrophy sections before you start, and ask about generic bimatoprost — it is the same molecule at a third of the price.
The verdict
This is the approved original that the compounded and generic lash serums in this register are copies of, and its efficacy is the least ambiguous result we have recorded. At sixteen weeks, 78% of subjects achieved at least a one-grade improvement on the Global Eyelash Assessment against 18% on vehicle. Lash length rose 1.4 mm — a 25% increase — against 0.1 mm. There is no interpretive work to do here: the drug does what it says.
The pack economics are unusually honest too. A 5 ml bottle ships with 140 single-use applicators, and the dosing instruction is one applicator per eye per night. That is 70 nights, stated by the manufacturer in the same paragraph as the fill volume. It is the only product in this register where the supply claim can be checked against the manufacturer's own component count without asking anyone anything.
Now the reason this is conditional rather than recommended. Increased brown iris pigmentation has occurred with bimatoprost and the label says it is likely to be permanent. Separately, postmarketing reports include periorbital fat atrophy producing a deepened eyelid sulcus and eyelid ptosis — a hollowing above the eye that is the opposite of what most people buying a lash serum in their thirties and forties are trying to achieve. And on stopping, lashes return to their pre-treatment level. This is a permanent-risk, temporary-benefit product.
The pricing is a lesson in itself. Brand Latisse averages around $214 for the 5 ml bottle. Generic bimatoprost starts near $61, and around $49 through some pharmacies. The Alloy service reviewed at R-32 sells the same generic molecule at the same strength for $175 a bottle — roughly three times the generic price — and its page does not mention the periorbitopathy this label carries.
- The largest, least ambiguous efficacy result in this register: 78% against 18%.
- Results published at weeks 1, 4, 8, 12, 16 and 20, not only at the endpoint.
- Digital image analysis of length, thickness and darkness reported separately from the investigator scale.
- Both fill volumes published with their applicator counts, so the supply claim is checkable.
- States explicitly that additional applications will not increase growth.
- States explicitly that lashes return to pre-treatment level on stopping.
- Instructs single use of each sterile applicator, and explains the bacterial keratitis risk behind it.
- Instructs not to apply to the lower lash line, and says why.
- Names periorbital fat atrophy, deepened eyelid sulcus, ptosis and madarosis in the postmarketing section.
- Warns that iris pigmentation is likely to be permanent, and describes how it spreads.
- Flags the interaction with prostaglandin analogues used for intraocular pressure.
- Declares benzalkonium chloride and its effect on soft contact lenses.
- Increased brown iris pigmentation may occur and is likely to be permanent.
- Postmarketing reports of periorbital fat atrophy, deepened eyelid sulcus and eyelid ptosis.
- Madarosis and eyelash breakage are also in the postmarketing section — lash loss from a lash drug.
- The benefit reverses entirely on stopping, so the risk is permanent and the result is not.
- One pivotal trial, 278 subjects, four months.
- Hair will grow wherever the solution repeatedly contacts skin.
- Should be used with caution in active intraocular inflammation and in those at risk of macular edema.
- Around $214 for the brand against roughly $61 for the identical generic.
- Cosmetic indication, so effectively never covered.
- The periorbitopathy is in postmarketing rather than in the warnings section, which is where people look.
Every active, assessed
- Bimatoprost0.03% — 0.3 mg/mL
Prostaglandin analogue — extends the anagen growth phase of the eyelash follicle and increases the number of hairs in it
- BENCHMARK
- 0.03% is the approved and trialled concentration for this indication
- ASSESSMENT
- The only concentration studied for hypotrichosis, and the same solution marketed as Lumigan for intraocular pressure. The mechanism is the reason for both the benefit and the harms: a prostaglandin analogue acting on hair follicles also acts on melanocytes and on orbital adipose tissue, and neither of those effects can be dialled out of it.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| BimatoprostProstaglandin analogue — extends the anagen growth phase of the eyelash follicle and increases the number of hairs in it | 0.03% — 0.3 mg/mL | 0.03% is the approved and trialled concentration for this indication | The only concentration studied for hypotrichosis, and the same solution marketed as Lumigan for intraocular pressure. The mechanism is the reason for both the benefit and the harms: a prostaglandin analogue acting on hair follicles also acts on melanocytes and on orbital adipose tissue, and neither of those effects can be dialled out of it. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%84/100
A multicentre, double-masked, randomised, vehicle-controlled trial in 278 adults with a prespecified primary endpoint, results at five timepoints and digital image analysis of length, thickness and darkness alongside the investigator scale. The effect size is large and consistent. Marked down for a single pivotal trial of modest size and a four-month duration on a product used for years.
- FORMULATION INTEGRITYWEIGHT 20%74/100
A sterile ophthalmic solution supplied with single-use applicators and an explicit instruction not to reuse them, which is the right answer to the bacterial keratitis risk of multi-dose ophthalmic containers. Marked down for benzalkonium chloride, which is absorbed by soft contact lenses and discolours them, and because the delivery relies entirely on the user applying it to the upper lid margin only.
- DISCLOSUREWEIGHT 15%92/100
Eight separate warning sections, results at every measured timepoint, both fill volumes with their applicator counts, an explicit statement that more product will not grow more lashes, an explicit statement that the effect reverses on stopping, and a postmarketing section that names periorbital fat atrophy, ptosis and madarosis. Held back only because the periorbitopathy sits in postmarketing rather than in the warnings, where a reader is more likely to find it.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed. The label reports eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye and periorbital erythema, each in under 4% of patients. A panel would need to run long enough to say anything useful about the pigmentation and sulcus changes, which develop over months to years.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. The applicator technique is the whole product — too much solution runs onto the cheek and grows hair there — and that is a panel question rather than a formulation one.
- COST PER APPLICATIONWEIGHT 10%66/100
Around $214 for 5 ml and 140 applicators is $3.06 a night for the brand — computable, because both numbers are printed. Generic bimatoprost at around $61 brings that under a dollar. Marked down because the brand premium buys nothing measurable, and because the indication is cosmetic so coverage is effectively absent.
What it is
Bimatoprost 0.03% as a sterile ophthalmic solution, applied nightly to the upper lash line with a single-use applicator, approved to treat hypotrichosis of the eyelashes by increasing length, thickness and darkness. Supplied as 3 ml with 70 applicators or 5 ml with 140. Around $214 for the brand; generic bimatoprost from about $61.
The efficacy is not in doubt
Latisse N=137 against vehicle N=141. Week 16 was the prespecified primary endpoint. The curve is the useful part: almost nothing at week 4, half the subjects by week 8, and the plateau reached by week 16 rather than week 20.
Digital image analysis at week 16 gives the physical measurement: lash length increased by 1.4 mm, a 25% rise, against 0.1 mm and 2% on vehicle. Fullness and darkness improved significantly too.
Set 78% against 18% beside the rest of this register: Renova's 60% against 39% for fine wrinkles, Winlevi's 18.8% against 8.7% for acne, Rhofade's 12% to 18% for facial redness. Lash growth is the one thing in this entire catalogue where a topical drug produces a change most people will unambiguously see. It is worth being clear about that before spending the rest of the review on the reasons to hesitate.
Two permanent things and one temporary one
The benefit stops when you stop. The label states it in the dosing section: 'Upon discontinuation of treatment, eyelash growth is expected to return to its pre-treatment level.' Two of the risks do not follow the same rule.
Patients should be advised about the potential for increased brown iris pigmentation which is likely to be permanent.
FDA-approved labelling, Warnings and Precautions 5.2
The mechanism is increased melanin inside existing melanocytes rather than more melanocytes. It spreads concentrically from the pupil outward, may take months to years to become noticeable, and the label says treatment can be continued in patients who develop it. Whether that is acceptable depends entirely on what colour your irises are now and how much you would mind.
In the postmarketing section: 'periorbital and lid changes associated with periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus and eyelid ptosis.' In plain terms, the fat pad behind the upper eyelid can shrink, hollowing the socket and dropping the lid. This is prostaglandin-associated periorbitopathy, and it is well described in the ophthalmic literature for this drug class. For a product bought overwhelmingly by people trying to look less tired, it is precisely the wrong side effect — and it is the one we found nowhere on the compounded and generic sellers' pages.
Also in postmarketing: madarosis and trichorrhexis — temporary loss of a few lashes to loss of sections of eyelashes, and eyelash breakage. A lash drug that can, occasionally, cost you lashes.
The supply arithmetic, which for once works
Two fill sizes, each with its applicator count: 3 ml with 70 applicators, 5 ml with 140. The dosing section says one applicator per eye, discarded after a single use, every night.
That table is only possible because the applicator count is printed beside the volume. Almost nothing else in this register supports the same calculation, and the contrast with R-32 is instructive: Alloy sells this same generic molecule, at this same strength, in this same 5 ml volume, and its page's three-month supply claim does not survive the applicator count.
If you are considering it
- Ask for generic bimatoprost. It is the identical molecule at the identical strength and the price difference is roughly threefold.
- Look at your irises and decide in advance. The pigmentation is likely to be permanent.
- Look at your upper eyelids and decide in advance. Sulcus deepening and ptosis are on this label.
- Upper lash line only. Never the lower — hair grows where the solution touches skin.
- One applicator per eye, discarded after use. Reusing them is how people get bacterial keratitis.
- Blot any runoff toward the cheek immediately.
- Remove contact lenses first and wait 15 minutes; the benzalkonium chloride discolours soft lenses.
- If you use a prostaglandin analogue for glaucoma, this is a conversation with your ophthalmologist, not a purchase.
- Expect nothing at four weeks, half the effect by eight, and the plateau by sixteen.
- Understand that stopping returns you to baseline, so the commitment is ongoing.
Where we stand
At 81 this is a high score for a product we have marked conditional, and the two are not in tension. Latisse does what it claims, measured properly, with the numbers published at every timepoint and the pack sized so you can check the supply yourself. The disclosure is close to exemplary.
What makes it conditional is a specific asymmetry: the benefit is real and reversible, and two of the harms are real and not. That is a legitimate trade for someone who wants it badly enough and has read the label. It is not a trade anyone should make from a product page that mentions neither the iris nor the eyelid — which is what R-32 found, and why this review exists.
Who this is for
- Someone with genuinely sparse lashes who has read the iris and eyelid sections and accepts them.
- Someone with darker irises already, for whom the pigmentation risk is less visible — though not absent.
- Someone who will use the single-use applicators as directed and only on the upper lid margin.
- Someone buying the generic, having established that the brand premium buys nothing.
- Someone who understands they are committing to an ongoing product, because the effect reverses.
- You have blue, green or hazel irises and would mind them going brown permanently.
- You are already worried about hollowing or heaviness of the upper eyelid — this can deepen the sulcus and cause ptosis.
- You use a prostaglandin analogue for glaucoma or ocular hypertension without your ophthalmologist's involvement.
- You have active uveitis or known risk factors for macular edema.
- You are pregnant or breastfeeding — the animal reproductive data are not reassuring and the indication is cosmetic.
- You want a permanent result. Stopping returns lashes to baseline.
We earn nothing on this link. Read the iris pigmentation and periorbital fat atrophy sections before you start, and ask about generic bimatoprost — it is the same molecule at a third of the price.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01FDA-approved labelling — LATISSE (bimatoprost ophthalmic solution) 0.03%, Allergan, Inc. The 0.3 mg/mL strength; the 278-subject vehicle-controlled trial with Global Eyelash Assessment results at weeks 1, 4, 8, 12, 16 and 20 (78% against 18% at the week-16 primary endpoint); the 1.4 mm and 25% length increase against 0.1 mm and 2%; the eight warning sections including permanent iris pigmentation, lid pigmentation, hair growth outside the treatment area, intraocular inflammation, macular edema, applicator contamination and contact lenses; the postmarketing reports of periorbital fat atrophy, deepened eyelid sulcus, eyelid ptosis, madarosis and trichorrhexis; the statement that additional applications will not increase growth and that lashes return to pre-treatment level on stopping; and the 3 ml/70 applicator and 5 ml/140 applicator pack configurations. Read 2 August 2026.
- S-02GoodRx — Latisse and generic bimatoprost pricing An average of about $213.81 for a 5 mL bottle of brand Latisse without insurance, against generic bimatoprost from around $61.18. Retrieved 2 August 2026.